---
title: Peptide Technologies Database
description: Comprehensive database of peptide technologies including synthesis, delivery, analysis, and computational methods for peptide research and development
category: technologies
total_technologies: 40
last_updated: 2026-06-13
---

# Peptide Technologies Database

A comprehensive collection of peptide technologies organized by category: Synthesis, Delivery, Analysis, and Computational.

## Categories Overview

| Category | Count | Description |
|----------|-------|-------------|
| Synthesis Technologies | 10 | Methods for peptide bond formation and assembly |
| Delivery Technologies | 10 | Systems for peptide administration and transport |
| Analysis Technologies | 10 | Techniques for peptide characterization |
| Computational Technologies | 10 | In silico methods for peptide design and prediction |

---

## Synthesis Technologies

Technologies for chemical, enzymatic, and recombinant peptide synthesis.

---

### Microwave-Assisted SPPS

| Property | Value |
|----------|-------|
| **ID** | TECH-SYN-001 |
| **Technology Name** | Microwave-Assisted Solid-Phase Peptide Synthesis |
| **Description** | Utilizes microwave irradiation to accelerate coupling reactions during solid-phase peptide synthesis, reducing synthesis time and improving crude purity |
| **原理** | Microwave energy generates rapid, uniform heating of reaction mixtures, enhancing molecular collision frequency and reducing activation energy barriers for amide bond formation. Dielectric heating directly excites polar molecules, achieving temperatures of 50-80°C within seconds |
| **Applications** | Difficult sequences, aggregation-prone peptides, long peptides (>50 residues), combinatorial library synthesis, cyclic peptides, peptide-drug conjugates |
| **Advantages** | 10-100x faster coupling cycles, reduced racemization, improved yields for difficult sequences, shorter overall synthesis time, better crude purity |
| **Limitations** | Equipment cost, potential epimerization at high temperatures, limited scalability beyond gram-scale, requires specialized vessels, not suitable for all protecting group strategies |
| **Current Status** | Commercially available (CEM Liberty Blue, Biotage Initiator+), widely adopted in research and pharmaceutical industry |
| **Category** | Synthesis Technologies |

---

### Flow Chemistry SPPS

| Property | Value |
|----------|-------|
| **ID** | TECH-SYN-002 |
| **Technology Name** | Flow Chemistry Solid-Phase Peptide Synthesis |
| **Description** | Continuous flow approach to SPPS where reagents are pumped through packed resin columns, enabling real-time monitoring and automated process control |
| **原理** | Reagent solutions are continuously pumped through a column containing peptide-loaded resin. Laminar flow ensures uniform reagent exposure, and inline UV/MS monitoring allows real-time coupling efficiency assessment. Residence time and temperature are precisely controlled |
| **Applications** | GMP manufacturing, process intensification, continuous production, API manufacturing, scale-up from milligram to kilogram quantities |
| **Advantages** | Consistent product quality, real-time monitoring, reduced solvent consumption, easier scale-up, reproducible process parameters, continuous manufacturing capability |
| **Limitations** | High initial setup cost, requires optimization of flow parameters, resin packing challenges, limited to sequences compatible with flow conditions |
| **Current Status** | Emerging commercial platforms, adopted by CDMOs for GMP production, growing pharmaceutical interest |
| **Category** | Synthesis Technologies |

---

### Automated SPPS

| Property | Value |
|----------|-------|
| **ID** | TECH-SYN-003 |
| **Technology Name** | Automated Solid-Phase Peptide Synthesis |
| **Description** | Fully automated robotic systems for high-throughput peptide synthesis with programmable protocols, multi-channel synthesis, and integrated purification |
| **原理** | Computer-controlled robotic platforms manage all synthesis steps: resin swelling, amino acid activation, coupling, deprotection, washing, and cleavage. Multiple peptides synthesized in parallel using arrays of reaction vessels or microfluidic chips |
| **Applications** | Peptide library generation, SAR studies, epitope mapping, high-throughput screening, parallel synthesis of hundreds to thousands of peptides |
| **Advantages** | High reproducibility, minimal human error, 24/7 operation, parallel synthesis of 96-384 peptides, standardized protocols, reduced labor costs |
| **Limitations** | High capital investment, maintenance requirements, limited flexibility for unusual chemistries, maximum sequence length constraints |
| **Current Status** | Mature technology with multiple vendors (CEM, Biotage, Gyros Protein Technologies, AAPPTec) |
| **Category** | Synthesis Technologies |

---

### Cell-Free Synthesis

| Property | Value |
|----------|-------|
| **ID** | TECH-SYN-004 |
| **Technology Name** | Cell-Free Peptide Synthesis |
| **Description** | In vitro transcription-translation systems that produce peptides without living cells, using cellular extracts or reconstituted systems |
| **原理** | Cell lysates (E. coli, wheat germ, rabbit reticulocyte) or PURE (Protein synthesis Using Recombinant Elements) systems provide ribosomes, tRNAs, and translation factors. Template DNA/mRNA directs ribosomal synthesis. Non-natural amino acids can be incorporated via engineered tRNAs |
| **Applications** | Toxic peptide production, membrane peptides, incorporation of non-natural amino acids, rapid prototyping, high-throughput expression screening |
| **Advantages** | No cell viability constraints, rapid setup (<2 hours), open reaction environment, easy incorporation of modified amino acids, scalable from µL to mL |
| **Limitations** | Low yields (typically µg/mL), high reagent cost, limited post-translational modifications, protein folding challenges, not cost-effective for large-scale production |
| **Current Status** | Commercial kits available (Promega, CellFree Sciences), growing adoption for difficult-to-express peptides |
| **Category** | Synthesis Technologies |

---

### Enzymatic Synthesis

| Property | Value |
|----------|-------|
| **ID** | TECH-SYN-005 |
| **Technology Name** | Enzymatic Peptide Synthesis |
| **Description** | Biocatalytic approach using proteases (reverse proteolysis) or ligases to form peptide bonds under mild aqueous conditions |
| **原理** | Thermodynamic control: proteases catalyze peptide bond formation by shifting equilibrium toward synthesis in high substrate concentrations or organic solvents. Kinetic control: use of acyl-donor esters with serine/cysteine proteases. Ligases (e.g., sortase A, butelase-1) join peptide fragments with high specificity |
| **Applications** | Fragile peptide synthesis, sugar-containing peptides, lipidated peptides, scale-up of therapeutic peptides, green chemistry applications |
| **Advantages** | No racemization, aqueous conditions, stereochemical fidelity, mild temperatures, compatible with sensitive functional groups, environmentally friendly |
| **Limitations** | Sequence-dependent efficiency, limited to protease recognition sites, lower yields for some sequences, enzyme cost, longer reaction times |
| **Current Status** | Commercially viable for specific peptides (Bachem, Lonza), growing interest in sustainable manufacturing |
| **Category** | Synthesis Technologies |

---

### Native Chemical Ligation

| Property | Value |
|----------|-------|
| **ID** | TECH-SYN-006 |
| **Technology Name** | Native Chemical Ligation (NCL) |
| **Description** | Chemoselective reaction between a C-terminal thioester and an N-terminal cysteine residue to form a native peptide bond, enabling synthesis of large proteins |
| **原理** | Transthioesterification between C-terminal thioester of one fragment and N-terminal cysteine thiol of another fragment, followed by spontaneous S-to-N acyl shift to form a native peptide bond at the ligation site. Requires cysteine or thiol-containing surrogate at the junction |
| **Applications** | Protein total synthesis, post-translationally modified proteins, mirror-image proteins, segmental isotopic labeling, protein engineering |
| **Advantages** | Chemoselective, aqueous conditions, no protecting groups needed, produces native peptide bond, compatible with most amino acids, enables synthesis of proteins up to ~300 residues |
| **Limitations** | Requires cysteine at ligation site (or surrogates), thioester synthesis can be challenging, racemization risk, slow kinetics for some junctions |
| **Current Status** | Gold standard for protein chemical synthesis, widely used in academic and pharmaceutical research |
| **Category** | Synthesis Technologies |

---

### Click Chemistry

| Property | Value |
|----------|-------|
| **ID** | TECH-SYN-007 |
| **Technology Name** | Click Chemistry Peptide Conjugation |
| **Description** | Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and strain-promoted variants (SPAAC) for bioorthogonal peptide conjugation and modification |
| **原理** | CuAAC: Cu(I) catalyzes [3+2] cycloaddition between azide and terminal alkyne to form 1,4-disubstituted 1,2,3-triazole. SPAAC: strained cyclooctynes react with azides without copper catalyst. Both proceed at physiological pH with high regioselectivity |
| **Applications** | Peptide-drug conjugates, PEGylation, fluorescent labeling, glycopeptide synthesis, biomaterial functionalization, bioconjugation, surface immobilization |
| **Advantages** | Bioorthogonal, high yields, chemoselective, aqueous-compatible, stable triazole linkage, modular design, no protecting groups needed |
| **Limitations** | Copper toxicity in CuAAC, steric constraints with bulky substrates, requires azide/alkyne incorporation, potential immunogenicity of triazole |
| **Current Status** | Widely adopted research tool, several click chemistry-derived therapeutics in clinical trials |
| **Category** | Synthesis Technologies |

---

### Photochemical Synthesis

| Property | Value |
|----------|-------|
| **ID** | TECH-SYN-008 |
| **Technology Name** | Photochemical Peptide Synthesis |
| **Description** | Light-activated synthesis methods using photocaged protecting groups and photoinduced reactions for spatiotemporal control of peptide bond formation |
| **原理** | Photolabile protecting groups (e.g., nitroveratryl, coumaryl) are removed upon UV/visible light irradiation, exposing reactive functional groups. Photoinitiated radical reactions and [2+2] cycloadditions enable cyclization and crosslinking with precise spatial and temporal control |
| **Applications** | Photolithographic peptide array synthesis, light-controlled cyclization, spatially defined peptide surfaces, photopharmacology, photoresponsive biomaterials |
| **Advantages** | Spatiotemporal control, no chemical deprotection needed, orthogonal to standard chemistry, enables microarray fabrication, clean photolysis byproducts |
| **Limitations** | Light penetration depth, photodamage to sensitive residues (Trp, Tyr, Met), incomplete deprotection, specialized equipment needed, scalability challenges |
| **Current Status** | Established for peptide arrays (SPOT synthesis), emerging in photopharmacology and smart materials |
| **Category** | Synthesis Technologies |

---

### Electrochemical Synthesis

| Property | Value |
|----------|-------|
| **ID** | TECH-SYN-009 |
| **Technology Name** | Electrochemical Peptide Synthesis |
| **Description** | Redox-driven peptide synthesis using electrochemical oxidation or reduction for protecting group removal and bond formation |
| **原理** | Electrochemical oxidation of thiol protecting groups (e.g., acetamidomethyl, Acm) at controlled electrode potentials enables selective deprotection. Cathodic reduction removes certain N-protecting groups. Electron transfer mediators can be used for indirect electrochemical deprotection |
| **Applications** | Cysteine-rich peptide synthesis, disulfide bond formation, orthogonal deprotection strategies, automated synthesis platforms, green chemistry approaches |
| **Advantages** | Precise redox control, no chemical oxidants/reductants needed, mild conditions, selective deprotection, reduced waste, compatible with flow systems |
| **Limitations** | Electrode fouling, limited to redox-labile groups, requires specialized electrochemical cells, scale-up challenges, potential over-oxidation |
| **Current Status** | Active research area, emerging commercial applications, growing interest in sustainable synthesis |
| **Category** | Synthesis Technologies |

---

### Mechanochemical Synthesis

| Property | Value |
|----------|-------|
| **ID** | TECH-SYN-010 |
| **Technology Name** | Mechanochemical Peptide Synthesis |
| **Description** | Solvent-free or minimal-solvent peptide synthesis using mechanical force (ball milling, grinding) to drive chemical reactions |
| **原理** | Mechanical energy from ball milling or grinding provides activation energy for peptide bond formation. High-energy collisions between milling balls and solid reactants create localized heating and fresh surfaces, enabling coupling reactions without bulk solvents. Liquid-assisted grinding (LAG) uses catalytic solvent amounts |
| **Applications** | Green peptide synthesis, solvent-free manufacturing, dipeptide and tripeptide production, pharmaceutical cocrystal synthesis, sustainable chemistry |
| **Advantages** | Dramatically reduced solvent waste, shorter reaction times, no bulk solvents, energy efficient, scalable, avoids solubility issues |
| **Limitations** | Limited to short peptides, racemization concerns, difficult to monitor in situ, product isolation challenges, not suitable for all amino acid combinations |
| **Current Status** | Emerging research field, proof-of-concept demonstrated, not yet commercially viable for long peptides |
| **Category** | Synthesis Technologies |

---

## Delivery Technologies

Systems and methods for peptide drug administration and targeted transport.

---

### Nanoparticle Delivery

| Property | Value |
|----------|-------|
| **ID** | TECH-DEL-001 |
| **Technology Name** | Nanoparticle Peptide Delivery |
| **Description** | Polymeric and lipid nanoparticles (PLGA, PLA, chitosan, solid lipid nanoparticles) encapsulating peptides for enhanced stability and controlled release |
| **原理** | Peptides are encapsulated within or adsorbed onto nanoparticles (50-500 nm) during fabrication (nanoprecipitation, emulsion, layer-by-layer). Biodegradable polymers (PLGA) release peptides through diffusion and erosion. Lipid nanoparticles fuse with cell membranes for intracellular delivery |
| **Applications** | Oral peptide delivery, sustained release formulations, brain delivery, cancer targeting, vaccine adjuvants, mucosal delivery |
| **Advantages** | Protection from enzymatic degradation, sustained release over days-weeks, targeting ligand conjugation, improved bioavailability, scalable manufacturing |
| **Limitations** | Burst release, peptide stability during encapsulation, batch-to-batch variability, regulatory complexity, immunogenicity of some materials |
| **Current Status** | Multiple FDA-approved nanoparticle products, extensive clinical pipeline, well-established manufacturing |
| **Category** | Delivery Technologies |

---

### Liposomal Delivery

| Property | Value |
|----------|-------|
| **ID** | TECH-DEL-002 |
| **Technology Name** | Liposomal Peptide Delivery |
| **Description** | Lipid vesicle delivery systems (conventional, PEGylated, targeted) for peptide encapsulation and transport across biological barriers |
| **原理** | Phospholipid bilayer self-assembly creates vesicles (50 nm - 5 µm) with aqueous interior for hydrophilic peptide encapsulation. Lipophilic peptides partition into the bilayer. PEGylation (stealth liposomes) extends circulation time. Targeting ligands enable cell-specific uptake via receptor-mediated endocytosis |
| **Applications** | Cancer therapy, intracellular peptide delivery, sustained systemic delivery, vaccine delivery, gene therapy, diagnostic imaging |
| **Advantages** | Biocompatible, biodegradable, high loading capacity, reduced immunogenicity, controlled release, versatile composition, clinical validation |
| **Limitations** | Manufacturing complexity, stability/shelf-life challenges, complement activation (CARPA), endosomal entrapment, cost of production |
| **Current Status** | Established platform technology, multiple marketed products (Doxil, Onivyde), extensive clinical use |
| **Category** | Delivery Technologies |

---

### Microneedle Delivery

| Property | Value |
|----------|-------|
| **ID** | TECH-DEL-003 |
| **Technology Name** | Microneedle Peptide Delivery |
| **Description** | Transdermal delivery using arrays of micron-scale needles (25-1000 µm) that painlessly penetrate the stratum corneum to deliver peptides into the skin |
| **原理** | Solid, coated, hollow, or dissolving microneedles create transient aqueous channels in the stratum corneum. Dissolving microneedles (hyaluronic acid, PVP, trehalose) release peptide cargo upon insertion. Skin interstitial fluid dissolves the matrix, releasing encapsulated peptides for local or systemic absorption |
| **Applications** | Insulin delivery, vaccine administration, hormone replacement, cosmetic peptides, pain management, self-administration devices |
| **Advantages** | Painless administration, self-applicable, no cold chain for dissolving types, improved patient compliance, bypasses first-pass metabolism, minimal sharps waste |
| **Limitations** | Limited peptide dose per patch, skin irritation, manufacturing precision requirements, variable insertion depth, regulatory pathway complexity |
| **Current Status** | Clinical trials for multiple peptide products, Vaxxas and Corium advancing platforms, growing commercial interest |
| **Category** | Delivery Technologies |

---

### Pulmonary Delivery

| Property | Value |
|----------|-------|
| **ID** | TECH-DEL-004 |
| **Technology Name** | Pulmonary Peptide Delivery |
| **Description** | Inhalation delivery of peptides to the lungs using dry powder inhalers (DPI), metered-dose inhalers (MDI), or nebulizers for local or systemic action |
| **原理** | Aerosolized peptide particles (1-5 µm for deep lung deposition) are inhaled and deposited in the alveolar region. Large surface area (~100 m²) and thin alveolar epithelium enable rapid absorption. Particle engineering (spray drying, milling) optimizes aerodynamic properties and stability |
| **Applications** | Inhaled insulin (Afrezza), pulmonary hypertension, lung fibrosis, systemic delivery of peptide hormones, respiratory infections |
| **Advantages** | Large absorptive surface area, rapid systemic absorption, avoids first-pass metabolism, non-invasive, patient self-administration |
| **Limitations** | Lung clearance mechanisms, variable deposition patterns, device-dependent delivery, peptide aggregation in dry powder, mucociliary clearance |
| **Current Status** | Afrezza (inhaled insulin) FDA-approved, multiple clinical programs, established DPI/MDI technology |
| **Category** | Delivery Technologies |

---

### Nasal Delivery

| Property | Value |
|----------|-------|
| **ID** | TECH-DEL-005 |
| **Technology Name** | Nasal Peptide Delivery |
| **Description** | Intranasal administration for local nasal action or nose-to-brain delivery via olfactory and trigeminal nerve pathways |
| **原理** | Peptides deposited in the nasal cavity are absorbed through the respiratory epithelium (systemic delivery) or transport along olfactory neurons to the brain (nose-to-brain). Absorption enhancers (chitosan, cyclodextrins, cell-penetrating peptides) improve permeation across nasal mucosa |
| **Applications** | Nose-to-brain delivery (Alzheimer's, Parkinson's, depression), intranasal insulin, oxytocin delivery, migraine treatment, vaccine administration |
| **Advantages** | Non-invasive brain targeting, bypasses blood-brain barrier, rapid onset, avoids first-pass metabolism, patient-friendly, self-administration |
| **Limitations** | Limited dose volume (~150 µL per nostril), mucociliary clearance, nasal enzymatic degradation, variable absorption, nasal irritation |
| **Current Status** | FDA-approved nasal peptide products (Migranal, Syntocinon), active nose-to-brain research, intranasal insulin in clinical trials |
| **Category** | Delivery Technologies |

---

### Oral Delivery

| Property | Value |
|----------|-------|
| **ID** | TECH-DEL-006 |
| **Technology Name** | Oral Peptide Delivery |
| **Description** | Gastro-resistant oral formulations using enteric coatings, permeation enhancers, and nanocarriers to enable oral peptide bioavailability |
| **原理** | Enteric coatings (Eudragit, HPMC-AS) prevent gastric degradation. Permeation enhancers (SNAC, salcaprozate sodium) transiently open tight junctions in intestinal epithelium. Nanocarriers protect peptides and promote lymphatic uptake. Mucoadhesive systems increase intestinal residence time |
| **Applications** | Oral semaglutide (Rybelsus), oral insulin, oral calcitonin, oral GLP-1 agonists, oral peptide vaccines |
| **Advantages** | Patient compliance, non-invasive, convenient self-administration, established manufacturing, large market potential |
| **Limitations** | Low bioavailability (typically <1-2%), variable absorption, food effects, gastrointestinal degradation, high permeation enhancer doses required |
| **Current Status** | Rybelsus (oral semaglutide) FDA-approved, multiple oral peptide programs in clinical trials, Novo Nordisk and Oramed leading development |
| **Category** | Delivery Technologies |

---

### Implantable Delivery

| Property | Value |
|----------|-------|
| **ID** | TECH-DEL-007 |
| **Technology Name** | Implantable Peptide Delivery |
| **Description** | Subcutaneous or intramuscular implant devices for sustained peptide release over weeks to months, including biodegradable and non-biodegradable systems |
| **原理** | Polymer matrices (PLGA, PCL) or osmotic pump devices release peptides through diffusion, erosion, or osmotic pressure. Biodegradable implants dissolve after drug depletion. Non-reservoir systems (Ozurdex-type) provide constant release kinetics. In situ forming implants (Eligard) form depot upon injection |
| **Applications** | Hormone replacement (testosterone, estradiol), cancer therapy (leuprolide), contraception, diabetes management (exenatide), chronic pain management |
| **Advantages** | Sustained release (1-6 months), reduced dosing frequency, improved patient compliance, consistent drug levels, removal capability for non-degradable systems |
| **Limitations** | Surgical insertion/removal, infection risk, implant migration, fibrous encapsulation, dose adjustment difficulty, manufacturing complexity |
| **Current Status** | Multiple FDA-approved products (Lupron Depot, Ozurdex, Nexplanon), established clinical use |
| **Category** | Delivery Technologies |

---

### Hydrogel Delivery

| Property | Value |
|----------|-------|
| **ID** | TECH-DEL-008 |
| **Technology Name** | Hydrogel Peptide Delivery |
| **Description** | Crosslinked polymer networks (natural or synthetic) that swell in water to encapsulate and release peptides through diffusion, degradation, or stimuli-responsive mechanisms |
| **原理** | Hydrophilic polymer chains (PEG, alginate, hyaluronic acid, PNIPAM) are crosslinked chemically, physically, or enzymatically to form 3D networks. Peptides are entrapped during gelation. Release occurs through diffusion from the swollen network, network degradation, or environmental triggers (pH, temperature, enzymes) |
| **Applications** | Wound healing, tissue engineering scaffolds, local cancer therapy, injectable depots, contact lenses, 3D cell culture, regenerative medicine |
| **Advantages** | Tunable properties, injectable formulations, sustained local delivery, biocompatible, can incorporate multiple peptides, tissue-mimetic environment |
| **Limitations** | Burst release, mechanical weakness, batch variability, sterilization challenges, peptide-matrix interactions may reduce activity |
| **Current Status** | Multiple commercial products, active research in smart/responsive hydrogels, growing clinical applications |
| **Category** | Delivery Technologies |

---

### Exosome Delivery

| Property | Value |
|----------|-------|
| **ID** | TECH-DEL-009 |
| **Technology Name** | Exosome Peptide Delivery |
| **Description** | Natural extracellular vesicles (30-150 nm) engineered to carry peptide cargo for targeted intracellular delivery with inherent biocompatibility |
| **原理** | Exosomes are secreted by cells and carry proteins, peptides, and nucleic acids. They are isolated by ultracentrifugation, size exclusion, or immunoaffinity. Peptides are loaded via electroporation, sonication, or co-incubation. Surface engineering with targeting ligands enables cell-specific delivery. Natural membrane proteins facilitate cellular uptake |
| **Applications** | Brain delivery, cancer immunotherapy, regenerative medicine, anti-inflammatory therapy, targeted intracellular peptide delivery |
| **Advantages** | Natural biocompatibility, low immunogenicity, inherent targeting ability, crosses blood-brain barrier, protects cargo from degradation, cell-specific delivery |
| **Limitations** | Low loading efficiency, batch-to-batch variability, scalability challenges, purification complexity, characterization difficulties, high production cost |
| **Current Status** | Early clinical stage, Codiak and Evox Therapeutics advancing platforms, rapid research growth |
| **Category** | Delivery Technologies |

---

### Cell-Penetrating Peptides

| Property | Value |
|----------|-------|
| **ID** | TECH-DEL-010 |
| **Technology Name** | Cell-Penetrating Peptide (CPP) Delivery |
| **Description** | Short peptides (5-30 residues) that facilitate intracellular transport of conjugated or complexed cargo molecules across cell membranes |
| **原理** | CPPs (TAT, penetratin, polyarginine) are cationic and/or amphipathic peptides that interact with cell membrane components. They enter cells via direct translocation or endocytic pathways. Cargo is covalently conjugated (amide, thioether, disulfide bonds) or non-covalently complexed via electrostatic interactions |
| **Applications** | Intracellular protein delivery, siRNA delivery, cancer therapy, neurodegenerative disease, gene editing tools (CRISPR), imaging agents |
| **Advantages** | Efficient cellular uptake, low toxicity, sequence versatility, can deliver diverse cargo types, endosomal escape capability, modular design |
| **Limitations** | Endosomal trapping, lack of cell specificity, serum instability, limited in vivo efficacy, potential immunogenicity, charge-dependent toxicity |
| **Current Status** | Widely used in research, several clinical trials (Synophicoll, TD139), commercial reagents available |
| **Category** | Delivery Technologies |

---

## Analysis Technologies

Instrumental and biophysical techniques for peptide characterization and quality control.

---

### Mass Spectrometry

| Property | Value |
|----------|-------|
| **ID** | TECH-ANA-001 |
| **Technology Name** | Mass Spectrometry (MS) |
| **Description** | Analytical technique measuring mass-to-charge ratio (m/z) of ionized peptides for molecular weight determination, sequencing, and identification |
| **原理** | Peptides are ionized (ESI, MALDI) and separated by m/z in mass analyzers (TOF, Orbitrap, ion trap, quadrupole). Tandem MS (MS/MS) fragments peptides via CID, HCD, or ETD for de novo sequencing. High-resolution MS enables identification of modifications, truncations, and impurities |
| **Applications** | Peptide identification, molecular weight verification, sequencing, impurity profiling, quantification (SRM/MRM), proteomics, quality control, stability studies |
| **Advantages** | High sensitivity (femtomole), high mass accuracy (<1 ppm), structural information from MS/MS, versatile coupling (LC-MS, MALDI-TOF), rapid analysis |
| **Limitations** | Sample preparation requirements, ion suppression, matrix effects, instrument cost, expertise needed, not quantitative without standards |
| **Current Status** | Essential analytical tool, mature technology with continuous innovation (timsTOF, Astral), standard in pharmaceutical QC |
| **Category** | Analysis Technologies |

---

### NMR Spectroscopy

| Property | Value |
|----------|-------|
| **ID** | TECH-ANA-002 |
| **Technology Name** | Nuclear Magnetic Resonance (NMR) Spectroscopy |
| **Description** | Non-destructive spectroscopic technique providing atomic-level structural information about peptide conformation, dynamics, and interactions in solution |
| **原理** | Nuclear spins (¹H, ¹³C, ¹⁵N) in magnetic fields absorb and re-emit radiofrequency radiation at characteristic frequencies dependent on chemical environment. 2D experiments (COSY, NOESY, HSQC, TOCSY) provide through-bond and through-space correlations for complete structure determination. NOE-derived distance restraints enable 3D structure calculation |
| **Applications** | Solution structure determination, conformational analysis, peptide-receptor interactions, dynamics studies (ps-ns timescale), quality control, aggregation monitoring |
| **Advantages** | Atomic resolution, solution-state structures, dynamic information, non-destructive, no size limit for small peptides, detects multiple conformations |
| **Limitations** | Requires isotopic labeling (¹³C, ¹⁵N) for proteins >10 kDa, low sensitivity, overlapping signals, size limitation (~40 kDa), expensive instruments (600-1000 MHz) |
| **Current Status** | Gold standard for solution structures, 800+ MHz magnets available, methyl-TROSY extends size range, standard in pharmaceutical development |
| **Category** | Analysis Technologies |

---

### X-ray Crystallography

| Property | Value |
|----------|-------|
| **ID** | TECH-ANA-003 |
| **Technology Name** | X-ray Crystallography |
| **Description** | Determination of atomic-resolution 3D structures by analyzing diffraction patterns of X-rays passing through peptide or protein crystals |
| **原理** | Peptide crystals are exposed to monochromatic X-ray beams (synchrotron or rotating anode). Diffracted X-rays create patterns indexed by Bragg's law (nλ = 2d sinθ). Electron density maps are calculated by Fourier transform of diffraction intensities. Molecular replacement or experimental phasing solves the phase problem |
| **Applications** | High-resolution structure determination, drug design, enzyme mechanism studies, protein-ligand complex structures, structure-based drug design |
| **Advantages** | Atomic resolution (1-2 Å typical), no size limitation, well-established methods, PDB database (>200,000 structures), definitive atomic positions |
| **Limitations** | Requires crystals (often challenging), static structure (no dynamics), crystal packing artifacts, time-consuming, phase problem, radiation damage |
| **Current Status** | Mature technique, synchrotron and XFEL sources, automated crystallography pipelines, essential for drug discovery |
| **Category** | Analysis Technologies |

---

### Cryo-Electron Microscopy

| Property | Value |
|----------|-------|
| **ID** | TECH-ANA-004 |
| **Technology Name** | Cryo-Electron Microscopy (Cryo-EM) |
| **Description** | Single-particle analysis of flash-frozen peptide/protein samples using direct electron detectors for near-atomic resolution structures without crystallization |
| **原理** | Samples are vitrified in thin ice layers and imaged with transmission electron microscope using low-dose electrons. Direct electron detectors capture thousands of 2D projection images. Computational alignment and 3D reconstruction (RELION, cryoSPARC) generates high-resolution density maps. Sub-3 Å resolution enables atomic model building |
| **Applications** | Large peptide complexes, membrane peptide structures, conformational ensembles, drug-target complexes, flexible assemblies |
| **Advantages** | No crystallization needed, near-atomic resolution, captures multiple conformations, small sample amounts, growing speed of data collection |
| **Limitations** | Preferred for complexes >100 kDa, expensive instruments ($5-10M), data processing expertise, orientation bias, radiation damage, ice quality issues |
| **Current Status** | Resolution revolution ongoing, 2017 Nobel Prize, 200+ cryo-EM facilities worldwide, rapidly growing structural database |
| **Category** | Analysis Technologies |

---

### Circular Dichroism

| Property | Value |
|----------|-------|
| **ID** | TECH-ANA-005 |
| **Technology Name** | Circular Dichroism (CD) Spectroscopy |
| **Description** | Spectroscopic technique measuring differential absorption of left and right circularly polarized light to determine peptide secondary structure content |
| **原理** | Chiral chromophores (amide bonds, aromatic residues) absorb left and right circularly polarized light differently. Far-UV CD (190-250 nm) reports on backbone secondary structure: α-helix (208, 222 nm minima), β-sheet (218 nm minimum), random coil (200 nm minimum). Near-UV CD (250-350 nm) probes tertiary structure and aromatic environment |
| **Applications** | Secondary structure determination, folding/unfolding studies, stability assessment, ligand binding effects on structure, batch-to-batch consistency, formulation screening |
| **Advantages** | Rapid analysis (<5 min), small sample amounts (50-200 µg), solution state, temperature stability studies, inexpensive, routine quality control |
| **Limitations** | Low resolution (global structure only), concentration-dependent, buffer interference below 200 nm, no residue-specific information, overlapping spectral features |
| **Current Status** | Routine analytical technique, synchrotron CD extends wavelength range, used in pharmaceutical development and QC |
| **Category** | Analysis Technologies |

---

### Surface Plasmon Resonance

| Property | Value |
|----------|-------|
| **ID** | TECH-ANA-006 |
| **Technology Name** | Surface Plasmon Resonance (SPR) |
| **Description** | Label-free optical technique measuring real-time binding kinetics and affinity between peptides and target molecules using refractive index changes at sensor surfaces |
| **原理** | Peptide ligands are immobilized on gold sensor chips. Analyte solutions flow over the surface, and binding events change the local refractive index, detected as shifts in SPR angle. Real-time sensorgrams are fitted to binding models to extract association (ka), dissociation (kd), and equilibrium (KD) constants |
| **Applications** | Binding affinity determination, kinetics measurement, epitope mapping, fragment screening, lead optimization, biosimilar characterization, quality control |
| **Advantages** | Real-time kinetics, label-free, high sensitivity (pM-µM KD range), low sample consumption, quantitative, automated, reproducible |
| **Limitations** | Requires immobilization (may affect binding), mass transport limitations, surface effects, regeneration challenges, instrument cost, expertise needed |
| **Current Status** | Standard technique in drug discovery (Biacore, ProteOn), essential for biologics characterization, FDA-accepted for biosimilarity assessment |
| **Category** | Analysis Technologies |

---

### Isothermal Titration Calorimetry

| Property | Value |
|----------|-------|
| **ID** | TECH-ANA-007 |
| **Technology Name** | Isothermal Titration Calorimetry (ITC) |
| **Description** | Direct measurement of heat released or absorbed during peptide-ligand binding to determine thermodynamic parameters (ΔH, ΔS, ΔG, Ka, n) in a single experiment |
| **原理** | Ligand is titrated into peptide solution in an adiabatic calorimeter. Each injection generates heat (exothermic) or absorbs heat (endothermic) proportional to binding. Power compensation or heat measurement yields binding isotherms analyzed by non-linear least squares to extract Ka, ΔH, n, and calculated ΔG and ΔS |
| **Applications** | Binding thermodynamics, enthalpy/entropy contributions, stoichiometry determination, fragment screening, lead optimization, mechanistic studies |
| **Advantages** | Label-free, in-solution measurement, complete thermodynamic profile, no immobilization needed, measures all binding parameters simultaneously |
| **Limitations** | Moderate sensitivity (nM-µM KD), high protein consumption (mg quantities), slow throughput (1-2 hours per experiment), buffer matching critical |
| **Current Status** | Complementary to SPR, MicroCal (Malvern) instruments standard in biophysics labs, growing use in rational drug design |
| **Category** | Analysis Technologies |

---

### Dynamic Light Scattering

| Property | Value |
|----------|-------|
| **ID** | TECH-ANA-008 |
| **Technology Name** | Dynamic Light Scattering (DLS) |
| **Description** | Optical technique measuring Brownian motion of particles in solution to determine hydrodynamic radius, size distribution, and aggregation state |
| **原理** | Laser light scattered by particles in solution fluctuates due to Brownian motion. Autocorrelation of scattered intensity fluctuations yields diffusion coefficient (D). Hydrodynamic radius (Rh) is calculated via Stokes-Einstein equation (Rh = kT/6πηD). Polydispersity index (PDI) indicates size distribution breadth |
| **Applications** | Aggregation screening, formulation development, batch consistency, nanoparticle characterization, stability studies, quality control |
| **Advantages** | Rapid measurement (1-2 min), small sample volume (10-50 µL), non-invasive, in-solution measurement, automated, temperature-controlled |
| **Limitations** | Low resolution for polydisperse samples, sensitive to dust/contaminants, intensity bias toward larger particles, limited size range (1 nm - 6 µm) |
| **Current Status** | Routine QC technique, Malvern Zetasizer widely used, complementary to SEC-MALS and AUC |
| **Category** | Analysis Technologies |

---

### Atomic Force Microscopy

| Property | Value |
|----------|-------|
| **ID** | TECH-ANA-009 |
| **Technology Name** | Atomic Force Microscopy (AFM) |
| **Description** | Scanning probe microscopy technique providing nanoscale topographic imaging and mechanical property measurement of peptide assemblies and surfaces |
| **原理** | A sharp tip on a cantilever raster-scans the sample surface. Tip-sample interactions (van der Waals, electrostatic, mechanical) cause cantilever deflection detected by laser reflection onto a photodiode. Operating modes include contact, tapping (AC), and non-contact. Force spectroscopy measures mechanical properties at piconewton resolution |
| **Applications** | Amyloid fibril imaging, peptide self-assembly characterization, surface morphology, mechanical properties, single-molecule force spectroscopy, biomaterial surfaces |
| **Advantages** | Nanometer resolution, works in liquid/air/vacuum, no labeling needed, 3D topographic imaging, mechanical property mapping, single-molecule capability |
| **Limitations** | Slow scan speed, limited scan area (typically <100 µm), tip convolution effects, sample preparation artifacts, expertise required, not high-throughput |
| **Current Status** | Standard nanoscale characterization tool, high-speed AFM emerging, combined AFM-optical platforms available |
| **Category** | Analysis Technologies |

---

### Small-Angle X-ray Scattering

| Property | Value |
|----------|-------|
| **ID** | TECH-ANA-010 |
| **Technology Name** | Small-Angle X-ray Scattering (SAXS) |
| **Description** | Solution scattering technique providing low-resolution structural information about peptide shape, size, and oligomeric state without crystallization |
| **原理** | X-rays scattered by electron density inhomogeneities in solution produce intensity patterns at small angles (2θ < 5°). Scattering profiles I(q) vs. q (where q = 4πsinθ/λ) are analyzed to extract radius of gyration (Rg), maximum dimension (Dmax), and pair distance distribution P(r). Ab initio modeling reconstructs molecular envelopes |
| **Applications** | Solution shape determination, oligomeric state assessment, conformational changes, flexible/disordered peptides, aggregation monitoring, complementary to crystallography |
| **Advantages** | Solution state, no size limit, captures flexibility, rapid measurement, minimal sample preparation, low-resolution envelope determination |
| **Limitations** | Low resolution (10-50 Å), requires monodisperse samples, radiation damage, data interpretation ambiguity, buffer subtraction critical |
| **Current Status** | Synchrotron SAXS beamlines widely available, BioSAXS standard in structural biology, combined with SEC for improved data quality |
| **Category** | Analysis Technologies |

---

## Computational Technologies

In silico methods for peptide design, structure prediction, and molecular simulation.

---

### Molecular Dynamics

| Property | Value |
|----------|-------|
| **ID** | TECH-COMP-001 |
| **Technology Name** | Molecular Dynamics (MD) Simulation |
| **Description** | Numerical simulation of peptide molecular motion by solving Newton's equations of force for all atoms over time, revealing conformational dynamics |
| **原理** | Force fields (AMBER, CHARMM, OPLS) define potential energy functions for bonded (bonds, angles, dihedrals) and non-bonded (van der Waals, electrostatic) interactions. Newton's equations (F=ma) are integrated at 1-2 fs timesteps. Periodic boundary conditions and Particle Mesh Ewald for long-range electrostatics enable realistic simulations |
| **Applications** | Conformational sampling, protein folding, drug binding pathways, free energy calculations, membrane peptide interactions, flexibility analysis |
| **Advantages** | Atomic-level dynamics, no experimental structure required (with homology models), nanosecond-microsecond timescales, thermodynamic/kinetic properties, mechanism visualization |
| **Limitations** | Computational cost (µs simulations require GPU clusters), force field accuracy, sampling limitations, system size constraints, expertise needed |
| **Current Status** | GPU-accelerated (GROMACS, AMBER, OpenMM), millisecond simulations possible (Anton, Folding@home), standard in computational biophysics |
| **Category** | Computational Technologies |

---

### Docking Studies

| Property | Value |
|----------|-------|
| **ID** | TECH-COMP-002 |
| **Technology Name** | Molecular Docking Studies |
| **Description** | Computational prediction of preferred orientation and binding affinity of peptides in complex with target proteins or receptors |
| **原理** | Rigid or flexible docking algorithms search conformational and orientational space of peptide ligands within receptor binding sites. Scoring functions estimate binding free energy based on shape complementarity, electrostatics, hydrogen bonding, and desolvation. Peptide flexibility is handled by ensemble docking or flexible backbone methods |
| **Applications** | Virtual screening, lead optimization, binding mode prediction, peptide inhibitor design, protein-protein interaction prediction, fragment linking |
| **Advantages** | Fast screening of large libraries, structural insight into binding, cost-effective compared to experiments, guides experimental design, scalable |
| **Limitations** | Scoring function accuracy, protein flexibility handling, solvent effects approximation, false positives/negatives, limited for flexible peptides |
| **Current Status** | Standard drug discovery tool (AutoDock, Glide, HADDOCK), peptide-specific tools emerging (FlexPepDock, CABS-dock) |
| **Category** | Computational Technologies |

---

### QSAR

| Property | Value |
|----------|-------|
| **ID** | TECH-COMP-003 |
| **Technology Name** | Quantitative Structure-Activity Relationship (QSAR) |
| **Description** | Statistical modeling relating peptide structural descriptors to biological activity for activity prediction and rational design |
| **原理** | Molecular descriptors (physicochemical, topological, 3D) are calculated for peptide libraries. Multivariate regression (PLS, random forest, SVM) or classification models correlate descriptors with measured activity. Validated models predict activity of new sequences. Descriptors include hydrophobicity, charge, shape, and amino acid composition |
| **Applications** | Activity prediction, lead optimization, virtual screening, toxicity prediction, ADMET property estimation, peptide library design |
| **Advantages** | Rapid activity prediction, identifies key structural features, reduces experimental screening, interpretable models, applicable to diverse endpoints |
| **Limitations** | Domain of applicability, descriptor selection bias, overfitting risk, limited to training set chemical space, sequence-dependent models |
| **Current Status** | Established approach, integrated with machine learning, PEPstr and AntiCP tools available for peptide-specific QSAR |
| **Category** | Computational Technologies |

---

### Machine Learning

| Property | Value |
|----------|-------|
| **ID** | TECH-COMP-004 |
| **Technology Name** | Machine Learning for Peptide Analysis |
| **Description** | Application of ML algorithms (random forests, SVMs, gradient boosting) to peptide data for property prediction, classification, and design |
| **原理** | Features (sequence-derived, physicochemical, evolutionary) are extracted from peptide datasets. Supervised learning algorithms (RF, SVM, XGBoost, neural networks) learn patterns correlating features with properties (activity, stability, toxicity). Cross-validation and external validation ensure generalizability. Feature importance reveals design rules |
| **Applications** | Antimicrobial peptide prediction, cell-penetrating peptide identification, cleavage site prediction, half-life prediction, toxicity screening, peptide design |
| **Advantages** | Handles high-dimensional data, non-linear relationships, interpretable models (tree-based), fast prediction, handles missing data, feature selection |
| **Limitations** | Requires quality training data, feature engineering expertise, overfitting risk, limited extrapolation, model interpretability varies |
| **Current Status** | Widely applied in peptide science, tools like DBAASP, CAMPR3, and CellPPD use ML models, growing integration with deep learning |
| **Category** | Computational Technologies |

---

### Deep Learning

| Property | Value |
|----------|-------|
| **ID** | TECH-COMP-005 |
| **Technology Name** | Deep Learning for Peptide Science |
| **Description** | Neural network architectures (CNNs, RNNs, transformers) applied to peptide sequence analysis, property prediction, and generative design |
| **原理** | Deep neural networks learn hierarchical representations from raw peptide sequences or structural data. Convolutional neural networks detect local sequence motifs. Recurrent networks (LSTM) capture sequential dependencies. Transformers with attention mechanisms learn long-range interactions. Generative models (VAE, GAN) create novel peptide sequences |
| **Applications** | Sequence-function mapping, generative peptide design, activity prediction, AMP classification, MHC binding prediction, de novo sequence generation |
| **Advantages** | Automatic feature learning, handles raw sequences, captures complex patterns, state-of-the-art accuracy, scalable with data, generative capability |
| **Limitations** | Data hungry, black box models, computational cost, overfitting on small datasets, requires GPU hardware, limited interpretability |
| **Current Status** | Rapidly growing field, DeepAmpep, AMPScanner, and PepNet tools available, transformer models emerging for peptide tasks |
| **Category** | Computational Technologies |

---

### AlphaFold

| Property | Value |
|----------|-------|
| **ID** | TECH-COMP-006 |
| **Technology Name** | AlphaFold Protein Structure Prediction |
| **Description** | Deep learning system by DeepMind that predicts protein 3D structure from amino acid sequence with near-experimental accuracy |
| **原理** | End-to-end differentiable neural network processes multiple sequence alignments (MSAs) and structural templates. Evoformer module learns evolutionary and structural relationships through attention mechanisms. Structure module predicts 3D coordinates and confidence scores (pLDDT). AlphaFold2 achieved median GDT ~92 on CASP14. AlphaFold3 extends to complexes |
| **Applications** | Protein structure prediction, peptide-protein complex modeling, structure-based drug design, protein engineering, functional annotation |
| **Advantages** | Near-experimental accuracy, no experimental structure needed, fast prediction (minutes), covers most protein space, open source (AlphaFold2), comprehensive database |
| **Limitations** | Less reliable for intrinsically disordered regions, confidence drops for novel folds, limited for multi-state proteins, static structures, sequence homology dependent |
| **Current Status** | Revolutionary impact, >200M structures predicted, Nobel Prize in Chemistry 2024, AlphaFold3 released, standard tool in structural biology |
| **Category** | Computational Technologies |

---

### RoseTTAFold

| Property | Value |
|----------|-------|
| **ID** | TECH-COMP-007 |
| **Technology Name** | RoseTTAFold Structure Prediction |
| **Description** | Three-track neural network architecture by David Baker's lab for protein and protein complex structure prediction, integrating sequence, distance, and coordinate information |
| **原理** | Three-track architecture processes information at 1D (sequence), 2D (pairwise distances), and 3D (coordinates) levels simultaneously with information passing between tracks. Inspired by AlphaFold2 but with simplified architecture. RoseTTAFold2 handles protein complexes, nucleic acids, and small molecules. Faster training and inference than AlphaFold |
| **Applications** | Protein structure prediction, protein complex modeling, nucleic acid interactions, small molecule binding, protein design, rapid structure screening |
| **Advantages** | Fast prediction, handles complexes, open source, protein design capabilities, community-maintained, complementary to AlphaFold |
| **Limitations** | Slightly lower accuracy than AlphaFold2 for single chains, requires GPU, MSA quality dependent, less validated for novel folds |
| **Current Status** | Open source (GitHub), integrated with RFdiffusion for design, active development by Baker lab, growing adoption |
| **Category** | Computational Technologies |

---

### ProteinMPNN

| Property | Value |
|----------|-------|
| **ID** | TECH-COMP-008 |
| **Technology Name** | ProteinMPNN Protein Sequence Design |
| **Description** | Graph neural network for inverse protein folding - designing amino acid sequences that fold into desired 3D structures |
| **原理** | Given a target backbone structure, ProteinMPNN constructs a residue graph with spatial and sequential edges. Message passing neural network iteratively updates node (residue) and edge (pairwise) features. Decoder predicts amino acid probabilities at each position conditioned on backbone geometry and sequence context. Autoregressive sampling generates sequences |
| **Applications** | De novo protein design, enzyme engineering, peptide binder design, stability optimization, sequence recovery, functional protein creation |
| **Advantages** | High sequence recovery (>50%), fast design (seconds), better than Rosetta for many tasks, handles backbone flexibility, experimental validation demonstrated |
| **Limitations** | Backbone structure required as input, limited to natural amino acids, no direct function optimization, may need experimental validation, backbone generation separate step |
| **Current Status** | Widely adopted in protein design community, experimental success demonstrated, integrated with RFdiffusion pipeline, open source |
| **Category** | Computational Technologies |

---

### RFdiffusion

| Property | Value |
|----------|-------|
| **ID** | TECH-COMP-009 |
| **Technology Name** | RFdiffusion Protein Structure Generation |
| **Description** | Diffusion generative model for de novo protein backbone structure design, enabling creation of novel protein architectures and binders |
| **原理** | Based on denoising diffusion probabilistic model applied to protein backbone coordinates. Forward process adds noise to real protein structures. Reverse process (conditioned on RF) iteratively denoises to generate realistic backbones. Conditional generation enables design of binders, symmetrical assemblies, and enzyme scaffolds with specified constraints |
| **Applications** | De novo binder design, symmetric assembly creation, enzyme scaffold generation, constrained motif scaffolding, therapeutic protein design |
| **Advantages** | Generates novel architectures, conditional generation, handles complex design tasks, no template needed, experimental validation of designs, open source |
| **Limitations** | Sequence design requires ProteinMPNN, experimental validation still needed, computational cost for large proteins, limited function control, design success rate varies |
| **Current Status** | Breakthrough in de novo protein design, Baker lab leading development, experimental successes published, open source, active research area |
| **Category** | Computational Technologies |

---

### ESMFold

| Property | Value |
|----------|-------|
| **ID** | TECH-COMP-010 |
| **Technology Name** | ESMFold Language Model Structure Prediction |
| **Description** | Protein language model-based structure prediction by Meta AI that predicts 3D structure from sequence without multiple sequence alignments |
| **原理** | ESM-2 protein language model (15B parameters) learns evolutionary and structural patterns from 250M protein sequences through masked language modeling. ESMFold uses ESM-2 embeddings directly in a structure prediction head, bypassing MSA computation. End-to-end differentiable architecture predicts coordinates and confidence (pTM) in a single forward pass |
| **Applications** | Rapid structure prediction, metagenomic proteins, viral sequences, proteome-wide structure prediction, rapid screening, proteins with few homologs |
| **Advantages** | No MSA needed (60x faster than AlphaFold), single sequence input, competitive accuracy, rapid prediction, handles metagenomic sequences, open source |
| **Limitations** | Lower accuracy than AlphaFold2 with good MSAs, less reliable for novel folds, large model size, requires GPU, no complex prediction |
| **Current Status** | Open source (Meta AI), ESM Atlas of 600M+ predicted structures, integrated into research workflows, active development |
| **Category** | Computational Technologies |

---

## Technology Comparison Summary

### Synthesis Technology Comparison

| Technology | Speed | Scale | Purity | Cost |
|------------|-------|-------|--------|------|
| Microwave-Assisted SPPS | Fast | mg-g | High | Medium |
| Flow Chemistry SPPS | Medium | g-kg | High | High |
| Automated SPPS | Fast | mg-g | High | High |
| Cell-Free Synthesis | Hours | µg-mg | Medium | Medium |
| Enzymatic Synthesis | Slow | mg-g | High | Low |
| Native Chemical Ligation | Slow | mg-g | High | Medium |
| Click Chemistry | Fast | mg-g | High | Medium |
| Photochemical Synthesis | Fast | µg-mg | Medium | Medium |
| Electrochemical Synthesis | Medium | mg-g | High | Medium |
| Mechanochemical Synthesis | Fast | mg | Medium | Low |

### Delivery Technology Comparison

| Technology | Bioavailability | Onset | Duration | Invasiveness |
|------------|----------------|-------|----------|--------------|
| Nanoparticle | Variable | Hours | Days-Weeks | Injection |
| Liposomal | Variable | Hours | Days | Injection |
| Microneedle | Moderate | Minutes | Hours-Days | Minimal |
| Pulmonary | Moderate | Minutes | Hours | Non-invasive |
| Nasal | Low-Moderate | Minutes | Hours | Non-invasive |
| Oral | Very Low | Hours | Hours | Non-invasive |
| Implantable | High | Hours | Weeks-Months | Surgical |
| Hydrogel | Variable | Hours | Days-Weeks | Injection |
| Exosome | Unknown | Hours | Unknown | Injection |
| CPP | Variable | Minutes | Hours | Injection |

### Analysis Technology Comparison

| Technique | Resolution | Sample | Information | Throughput |
|-----------|------------|--------|-------------|------------|
| Mass Spectrometry | Da | µg | MW, sequence | High |
| NMR | Atomic | mg | Structure, dynamics | Low |
| X-ray Crystallography | Å | mg | 3D structure | Low |
| Cryo-EM | Å | µg | 3D structure | Low |
| Circular Dichroism | Global | µg | Secondary structure | High |
| SPR | Binding | µg | Kinetics, affinity | Medium |
| ITC | Thermodynamic | mg | ΔH, ΔS, Ka | Low |
| DLS | nm | µg | Size distribution | High |
| AFM | nm | µg | Topography | Low |
| SAXS | nm | mg | Shape, size | Medium |

### Computational Technology Comparison

| Method | Speed | Accuracy | Input | Output |
|--------|-------|----------|-------|--------|
| Molecular Dynamics | Hours-Days | High | Structure | Dynamics |
| Docking | Minutes | Medium | Structure | Binding mode |
| QSAR | Seconds | Medium | Descriptors | Activity |
| Machine Learning | Seconds | High | Features | Predictions |
| Deep Learning | Seconds-Minutes | High | Sequence | Properties |
| AlphaFold | Minutes | High | Sequence | Structure |
| RoseTTAFold | Minutes | High | Sequence | Structure |
| ProteinMPNN | Seconds | High | Backbone | Sequence |
| RFdiffusion | Minutes | High | Constraints | Backbone |
| ESMFold | Seconds | Medium-High | Sequence | Structure |

---

*Last updated: 2026-06-13 | Total technologies: 40*
